N/A N=100 Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)
Acute Decompensated Heart Failure
Primary: Total Urine Sodium Output — 1082; 423 mmol of sodium — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,437 TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Asthma
Primary: 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26 — 0.229; 0.157; 0.274 Liter — p=0.003
Phase 3 N=480 A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India
Healthy Volunteers
Primary: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity Within 7 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years…
Phase 2 N=9 Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Metastatic Melanoma · Stage III Melanoma · Stage IV Melanoma
Primary: Phase 1 Regimen Limiting Toxicity of the Combination of Indoximod and Ipilimumab — 0; 1 Participants
Phase 3 N=25 Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
Glabellar Frown Lines · Canthal Lines
Primary: Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines) — 100 percentage of participants
N/A N=53 Clinical Evaluation of Two Cosmetic Contact Lenses
Visual Acuity
Primary: Distance Monocular logMAR Visual Acuity — -0.159; -0.157 logMAR
Phase 3 N=360 Comparing Tissue Adhesives in Port Site Closure
Dermatitis, Contact
Primary: Number of Participants Who Develop Contact Dermatitis — 21; 18 Participants
Phase 3 N=117 Convalescent Plasma Collection and Treatment in Pediatrics and Adults
COVID19 · Coronavirus Infection · Coronavirus
Primary: Time of Meeting Infusion Criteria to Infusion — 1 days
N/A N=90 The ILLUMINATE Study
Healthy
Primary: Measurement Performance of Air Charged Catheter in cm — 4.10 cm
N/A N=452 Smoke-free Home Intervention in Permanent Supportive Housing
Smoking Cessation · Second Hand Tobacco Smoke
Primary: Proportion of Resident-participants Who Adopt a Smoke-free Home Voluntarily — 0.068; 0.048 proportion of resident-participants
Phase 2 N=108 Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
Hypersensitivity · Food Allergy · Hypersensitivity, Food
Primary: The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC) — 19; 27; 3 Participants — p=0.16
N/A N=3 Non-invasive Vagal Neurostimulation (nVNS) for Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress
Acute Respiratory Distress Syndrome · Acute Lung Injury · Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Primary: All-Cause 90-Day Admission to Any Hospital or ED Encounter — 0; 0 Participants
Phase 1 N=138 Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
HIV Infections
Primary: Part 1 Injection 1: Time of Maximum Observed Plasma Concentration (Tmax) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b & 4h — 197.731; 150.215; 122.009; 145.648…
Phase 2 N=39 Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Untreated Adult Acute Myeloid Leukemia
Primary: Biochemical Response — 0 Participants
Phase 2 N=56 Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
Chronic Graft Versus Host Disease
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 3; 3; 10; 0 participants